Previous results of asunercept have shown that low CpG2 methylation of the CD95L promoter was associated with greater asunercept responses and improved treatment outcome in both newly diagnosed and recurrent GBM patients, therefore representing a potential biomarker for indicating the asunercept treatment outcome [19,20]. The gene discussed is FASLG; the disease is glioblastoma.